

Total of patients in RAMQ database

Extraction criteria: all patients aged 18 and older who received a diagnosis of atrial fibrillation (AF) (medical claim or hospitalization) between 2005 and 2017	353,841
--	----------------

Inclusion criteria

Diagnosis of atrial fibrillation (AF) (medical claim or hospitalization) between 2013 and 2017	119,169	(Excluded) (234,672)
At least one dispensation of oral anticoagulant (warfarin or DOAC) within the year following the AF diagnosis. The date of the first anticoagulant dispensation was defined as the claim index date	65,329	(53,840)
Complete coverage by the RAMQ drug plan for the year preceding the claim index date	65,254	(75)
No warfarin and no DOAC in the year preceding the claim index date	49,945	(15,309)

Exclusion criteria

No valvular replacement/procedures in the 5 years preceding the claim index date	47,685	(Excluded) (2,260)
No end-stage renal disease or dialysis (for a minimal period of 3 continuous months) in the 3 years preceding the claim index date	47,498	(187)
No kidney transplant in the 3 years preceding the claim index date	47,494	(4)
No coagulation deficiency in the 3 years preceding the claim index date	47,480	(14)
No hip/knee/pelvis fracture in the 6 weeks preceding the claim index date	46,509	(971)
No catheterization, coronary cerebrovascular or defibrillator procedures during the 3 months preceding the claim index date	41,652	(4,857)
No absence of chronic kidney disease stage III	9,308	(32,344)

AMONG THE 9,308 PATIENTS

Number of users of:	
Warfarin:	3,335
Dabigatran 110 mg:	263
Dabigatran 150 mg:	146
Rivaroxaban 15 mg:	744
Rivaroxaban 20 mg:	1,064
Apixaban 2.5 mg:	1,674
Apixaban 5 mg:	2,082

OACs COMPARED

Rivaroxaban 15 mg
versus
warfarin

Rivaroxaban 20 mg
versus
warfarin

Apixaban 2.5 mg
versus
warfarin

Apixaban 5 mg
versus
warfarin